CD8A and neoplasm: Consequently, ICI administration should align with the peak of OV-primed T-cell exhaustion: for IT delivery, optimal ICI timing is Day 7–14 post-OV, coinciding with PD-1 upregulation on tumor-infiltrating CD8+ T cells; for IV delivery, delayed ICI initiation (Day 10–21) compensates for slower immune priming [105,154].